The corporate parent of Cambridge, MA-based Shire Human Genetic Therapies said today that it has wrapped up the submission of its FDA application for approval of velaglucerase alfa, an enzyme-replacement therapy for patients with Type 1 Gaucher’s disease. The company still needs FDA approval before it begins U.S. sales of the treatment. Cambridge-based Genzyme (NASDAQ:[[ticker:GENZ]]) sells the market-leading drug for Gaucher’s disease, imiglucerase (Cerezyme). Shire Human Genetic Therapies, which is developing velaglucerase alfa, is a unit of the Irish drug firm Shire (LSE:[[ticker:SHP]]).
Author: Ryan McBride
Ryan is an award-winning business journalist who contributes to our life sciences and technology coverage. He was previously a staff writer for Mass High Tech, a Boston business and technology newspaper, where he and his colleagues won a national business journalism award from the Society of American Business Editors and Writers in 2008. In recent years, he has made regular TV appearances on New England Cable News.
Prior to MHT, Ryan covered the life sciences, technology, and energy sectors for Providence Business News. He graduated with honors from the University of Rhode Island in 2001 with a bachelor’s degree in communications. When he’s not chasing down news, Ryan enjoys mountain biking and skiing in his home state of Vermont.
View all posts by Ryan McBride
